{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:44:48Z","timestamp":1790811888232,"version":"4.1.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Etranacogene dezaparvovec (AMT-061) is a recombinant adeno-associated virus serotype 5 (AAV5) vector containing a codon-optimized Padua variant human factor IX (FIX) transgene with a liver-specific promoter. Here, we report 3-year outcomes from a phase 2b, open-label, single-dose, single-arm, multicenter trial conducted among adults with severe or moderately severe hemophilia B (FIX \u22642%). All participants (n\u00a0= 3) received a single intravenous dose (2\u00a0\u00d7 1013 gene copies per kg) and will be followed up for 5 years. The primary end point of FIX activity \u22655% at 6 weeks was met. Secondary end points included bleed frequency, FIX concentrate use, joint health, and adverse events (AEs). All participants required routine FIX prophylaxis and had neutralizing antibodies to AAV5 before etranacogene dezaparvovec treatment. After administration, FIX activity rose to a mean of 40.8% in year 1 and was sustained in year 3 at 36.9%. All participants discontinued FIX prophylaxis. Bleeding was completely eliminated in 2 out of 3 participants. One participant required on-demand FIX replacement therapy per protocol because of elective surgical procedures, for 2 reported bleeding episodes, and twice for a single self-administered infusion because of an unreported reason. One participant experienced 2 mild, self-limiting AEs shortly after dosing. During the 3-year study period, there were no clinically significant elevations in liver enzymes, no requirement for steroids, no FIX inhibitor development, and no late-emergent safety events in any participant. Etranacogene dezaparvovec was safe and effective in adults with hemophilia B over 3 years after administration. This trial was registered at www.clinicaltrials.gov as #NCT03489291.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008886","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T18:37:31Z","timestamp":1670611051000},"page":"5671-5679","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":58,"title":["Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy"],"prefix":"10.1182","volume":"7","author":[{"given":"Annette","family":"von Drygalski","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, University of California San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Gomez","sequence":"additional","affiliation":[{"name":"2Center for Inherited Blood Disorders, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Giermasz","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, Hemophilia Treatment Center, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[{"name":"4Center for Bleeding Disorders, Department of Oncology, Careggi University Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel S.","family":"Key","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Blood Research Center, Department of Medicine, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan U.","family":"Lattimore","sequence":"additional","affiliation":[{"name":"6The Hemophilia Center, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W. G.","family":"Leebeek","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Miesbach","sequence":"additional","affiliation":[{"name":"8Department of Hemostaseology and Hemophilia Center, Medical Clinic 2, Institute of Transfusion Medicine, University Hospital Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2805-1016","authenticated-orcid":false,"given":"Michael","family":"Recht","sequence":"additional","affiliation":[{"name":"9American Thrombosis and Hemostasis Network, Rochester, NY"},{"name":"10Hemophilia Treatment Center, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gut","sequence":"additional","affiliation":[{"name":"11uniQure Inc, Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Dolmetsch","sequence":"additional","affiliation":[{"name":"11uniQure Inc, Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Monahan","sequence":"additional","affiliation":[{"name":"12CSL Behring, King of Prussia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6203-3946","authenticated-orcid":false,"given":"Sandra","family":"Le Quellec","sequence":"additional","affiliation":[{"name":"13CSL Behring Europe, Hattersheim am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[{"name":"14Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"suppl 6","key":"2023101015204900000_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"2023101015204900000_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.thromres.2016.02.030","article-title":"Nonacog beta pegol (N9-GP) in haemophilia B: a multinational phase III safety and efficacy extension trial (paradigm\u21224)","volume":"141","author":"Young","year":"2016","journal-title":"Thromb Res"},{"issue":"14","key":"2023101015204900000_bib3","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2023101015204900000_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/jcm6070063","article-title":"Pathophysiology of hemophilic arthropathy","volume":"6","author":"Melchiorre","year":"2017","journal-title":"J Clin Med"},{"issue":"3","key":"2023101015204900000_bib5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2023101015204900000_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/hae.13769","article-title":"How to discuss gene therapy for haemophilia? A patient and physician perspective","volume":"25","author":"Miesbach","year":"2019","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"2023101015204900000_bib7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2018-99-118334","article-title":"Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing empty viral particles on safety and efficacy of gene transfer","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2023101015204900000_bib8","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023101015204900000_bib9","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5\u2013human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"S1","key":"2023101015204900000_bib10","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2019-128765","article-title":"One year data from a phase 2b trial of AMT-061 (AAV5-Padua hFIX variant), an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia B","volume":"134","author":"Pipe","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2023101015204900000_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023101015204900000_bib12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"2023101015204900000_bib13","unstructured":"Dimension announces interim topline results from ongoing phase 1\/2 clinical program for DTX101, dimension\u2019s lead AAV product candidate in development for adult patients with moderate\/severe to severe hemophilia B. GlobeNewswire News Room. 31 January 2017. Accessed 22 December 2022. https:\/\/www.globenewswire.com\/news-release\/2017\/01\/31\/912410\/0\/en\/Dimension-Announces-Interim-Topline-Results-from-Ongoing-Phase-1-2-Clinical-Program-for-DTX101-Dimension-s-Lead-AAV-Product-Candidate-in-Development-for-Adult-Patients-with-Moderat.html."},{"issue":"3","key":"2023101015204900000_bib14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"issue":"suppl 2","key":"2023101015204900000_bib15","first-page":"90","article-title":"Five year data confirms stable FIX expression and sustained reductions in bleeding and factor IX use following AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B","volume":"5","author":"Miesbach","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"2023101015204900000_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.omtm.2019.09.005","article-title":"Enhanced factor IX activity following administration of AAV5-R338L \"Padua\" factor IX versus AAV5 WT human factor IX in NHPs","volume":"15","author":"Spronck","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"21","key":"2023101015204900000_bib17","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2023101015204900000_bib18","doi-asserted-by":"crossref","first-page":"e12690","DOI":"10.1002\/rth2.12690","article-title":"The hemophilia joint health score version 2.1 validation in adult patients study: a multicenter international study","volume":"6","author":"St-Louis","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"2023101015204900000_bib19","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/hae.13327","article-title":"Monitoring joint health in haemophilia: factors associated with deterioration","volume":"23","author":"Kuijlaars","year":"2017","journal-title":"Haemophilia"},{"issue":"5","key":"2023101015204900000_bib20","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/hae.12642","article-title":"Interpreting important health-related quality of life change using the Haem-A-QoL","volume":"21","author":"Wyrwich","year":"2015","journal-title":"Haemophilia"},{"key":"2023101015204900000_bib21","doi-asserted-by":"crossref","unstructured":"Itzler\n              R\n            , MillerJ, RobsonR, MonahanP, PipeS. Improvements in health-related quality of life in adults with severe or moderately severe hemophilia B after receiving etranacogene dezaparvovec gene therapy. ISTH Congress. Accessed 22 December 2022. https:\/\/abstracts.isth.org\/abstract\/improvements-in-health-related-quality-of-life-in-adults-with-severe-or-moderately-severe-hemophilia-b-after-receiving-etranacogene-dezaparvovec-gene-therapy\/.","DOI":"10.1055\/s-0042-1760525"},{"issue":"S3","key":"2023101015204900000_bib22","first-page":"108","article-title":"Health-related quality of life over 2 years following valoctocogene roxaparvovec adeno-associated virus gene transfer for severe haemophilia A: results from GENEr8-1","volume":"28","author":"Dunn","year":"2022","journal-title":"Haemophilia"},{"issue":"11","key":"2023101015204900000_bib23","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/mt.2010.175","article-title":"Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy","volume":"18","author":"Hurlbut","year":"2010","journal-title":"Mol Ther"},{"issue":"10","key":"2023101015204900000_bib24","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2023101015204900000_bib25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/mt.2009.245","article-title":"The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques","volume":"18","author":"Wang","year":"2010","journal-title":"Mol Ther"},{"issue":"5","key":"2023101015204900000_bib26","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2005-08-3229","article-title":"Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice","volume":"107","author":"Scallan","year":"2006","journal-title":"Blood"},{"issue":"S3","key":"2023101015204900000_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/hae.14027","article-title":"Delivering on the promise of gene therapy for haemophilia","volume":"27","author":"Pipe","year":"2021","journal-title":"Haemophilia"},{"issue":"25","key":"2023101015204900000_bib28","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2023101015204900000_bib29","first-page":"1","article-title":"A novel adeno associated virus (AAV) gene therapy (FLT180a) achieves normal FIX activity levels in severe hemophilia B (HB) patients (B-AMAZE study)","volume":"4","author":"Chowdary","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"2023101015204900000_bib30","doi-asserted-by":"crossref","unstructured":"Leebeek\n              F\n            , MeijerK, CoppensM, . AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B confirm stable FIX expression and durable reductions in bleeding and factor IX consumption for up to 5 years. ASH. Accessed 2 August 2022. https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper139225.html.","DOI":"10.1182\/blood-2020-139225"},{"key":"2023101015204900000_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"9","key":"2023101015204900000_bib32","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol Ther"},{"issue":"4","key":"2023101015204900000_bib33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.immuni.2018.03.013","article-title":"Toll-like receptor 9 contains two DNA binding sites that function cooperatively to promote receptor dimerization and activation","volume":"48","author":"Ohto","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"2023101015204900000_bib34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ymthe.2020.01.026","article-title":"Codon modification and PAMPs in clinical AAV vectors: the tortoise or the hare?","volume":"28","author":"Wright","year":"2020","journal-title":"Mol Ther"},{"issue":"suppl 1","key":"2023101015204900000_bib35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood-2018-99-118050","article-title":"A\u00a0single intravenous infusion of FLT180a results in Factor IX activity levels of more than 40% and has the potential to provide a functional cure for patients with haemophilia B","volume":"132","author":"Chowdary","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2023101015204900000_bib36","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.3390\/jcm10112471","article-title":"Emerging immunogenicity and genotoxicity considerations of adeno-associated virus vector gene therapy for hemophilia","volume":"10","author":"Monahan","year":"2021","journal-title":"J Clin Med"},{"issue":"17","key":"2023101015204900000_bib37","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2023101015204900000_bib38","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood-2019-122535","article-title":"Stable FIX expression and durable reductions in bleeding and factor IX consumption for up to 4 years following AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B","volume":"134","author":"Miesbach","year":"2019","journal-title":"Blood"},{"key":"2023101015204900000_bib39","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.12491.1","article-title":"Emerging therapies for hemophilia: controversies and unanswered questions","volume":"7","author":"Arruda","year":"2018","journal-title":"F1000Research"},{"issue":"11","key":"2023101015204900000_bib40","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"key":"2023101015204900000_bib41","unstructured":"Miesbach\n              W\n            , LeebeekFWG, RechtM, . Final analysis from the pivotal phase 3 HOPE-B gene therapy trial: stable steady-state efficacy and safety of etranacogene dezaparvovec in adults with severe or moderately severe hemophilia B. ISTH. Accessed 3 August 2022. https:\/\/genetherapy.isth.org\/final-analysis-from-the-pivotal-phase-3-hope-b-gene-therapy-trial-stable-steady-state-efficacy-and-safety-of-etranacogene-dezaparvovecin-adults-with-severe-or-moderately-severe-hemophilia-b."},{"issue":"21","key":"2023101015204900000_bib42","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2023101015204900000_bib43","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023101015204900000_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2023101015204900000_bib45","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2023101015204900000_bib46","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2019-129786","article-title":"Clearance of vector DNA following systemic administration of AAV5-hFIX or AAV5-hFIX Padua in patients with severe or moderate-severe hemophilia B","volume":"134","author":"Sawyer","year":"2019","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5671\/2083640\/blooda_adv-2022-008886-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5671\/2083640\/blooda_adv-2022-008886-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:26:37Z","timestamp":1696951597000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/19\/5671\/493567\/Stable-and-durable-factor-IX-levels-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":46,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,10,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008886","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}